Singapore Patients With Inherited Retinal Disease Back Genetic Testing, Especially When Access Looks Real
Among Singapore patients living with inherited retinal disease, support for genetic testing was broad, but it was not uniform. Understanding, cost coverage, age, ethnicity, and family history all shaped how people viewed testing and whether they would extend that support to reproductive decision-making.
This cross-sectional study surveyed 216 patients recruited through Singapore National Eye Centre and satellite clinics. The cohort had a median age of 57.5 years, 50.9% were male, and 85.6% were Chinese. Participants answered closed- and open-ended questions about their knowledge of genetic testing and their views on its use for reproductive interventions, including preimplantation genetic testing and prenatal testing.
The findings point to a practical gap between acceptance and comprehension. Many patients expressed approval of genetic testing, yet self-reported understanding varied widely. In a condition as genetically heterogeneous as IRD, that combination matters at the bedside because patients may endorse testing in principle without fully appreciating what the result can and cannot change for their own care or for future family planning.
Support for Testing Was Broad, But Knowledge Was Uneven
Overall, 62.5% of participants held a favorable view of genetic testing. Support also extended to reproductive applications: 56.5% were favorable toward preimplantation genetic testing, and 58.8% supported prenatal testing. Those numbers suggest that many patients already see genetic information as relevant beyond diagnosis alone, reaching into decisions about embryo selection and pregnancy management.
The survey also showed that attitudes were not simply a matter of abstract belief. Better self-reported understanding was strongly associated with support for genetic testing, with an odds ratio of 3.24 and a 95% confidence interval of 1.4 to 7.5. Similar patterns appeared for financial coverage, with an odds ratio of 3.29 and a 95% confidence interval of 1.4 to 7.9, and for universal availability, with an odds ratio of 4.44 and a 95% confidence interval of 1.8 to 10.7. Those associations suggest that patients are not only asking whether testing exists; they are asking whether it is understandable, affordable, and realistically accessible.
A single sentence captures the clinical tension: access changes attitudes.
Understanding, Cost, and Availability Moved Patient Opinion
The association between better self-reported understanding and stronger support has immediate implications for ophthalmic genetics clinics. When people understand the purpose of testing, the limits of what can be inferred, and how the result may affect relatives, their receptiveness rises. That pattern is especially important for IRD, where families often face uncertainty about inheritance patterns, risk to children, and whether a genetic diagnosis may alter reproductive choices.
Financial coverage emerged as another major lever. Patients were more supportive when testing was described as covered rather than privately paid. Universal availability carried the strongest association of the three access variables, suggesting that patients perceive a system-wide offer of testing as a signal of legitimacy and usefulness. In practice, this means that expansion of testing infrastructure may do more than increase test volume; it may change how patients interpret the value of the service itself.
The study’s qualitative component supports that reading, even though the abstract does not provide the detailed theme list. Open-ended responses were analyzed by thematic coding and frequency tabulation, which means the authors were looking not just for whether patients said yes or no, but for the reasons attached to those answers. In a genetics clinic, those reasons often determine whether counseling leads to uptake, refusal, or delay.
Age, Ethnicity, and Family History Shaped Views on Reproductive Uses
Support for preimplantation genetic testing was not evenly distributed across the sample. Chinese ethnicity was associated with greater support, with an odds ratio of 2.50 and a 95% confidence interval of 1.1 to 5.8. Younger age, defined here as under 50 years, was also associated with stronger support, with an odds ratio of 2.52 and a 95% confidence interval of 1.3 to 4.7. A positive family history carried a similar association, with an odds ratio of 2.03 and a 95% confidence interval of 1.1 to 3.8.
Those associations are clinically plausible. Younger patients are more likely to be actively considering future reproduction, and those with an affected relative may have seen firsthand how IRD affects vision across generations. Family history can make inherited risk more concrete, turning a molecular result from an abstract label into a personal reproductive issue. Ethnicity likely reflects a mix of cultural beliefs, family planning expectations, and attitudes toward medical technology, although the study design cannot separate those influences.
Genetic Counseling Needs to Match Patient Readiness
The clearest message from this study is not that patients reject testing. It is that many are ready for it, but readiness depends on whether the clinic can translate a genetic service into something understandable, affordable, and relevant to the patient’s future choices. Education and tailored genetic counseling could raise uptake and perceived usefulness, especially for people who report poorer understanding at baseline.
For ophthalmologists and counselors, this means the discussion should not stop at diagnosis. It should cover inheritance, uncertainty, reproductive options, and the real-world meaning of a positive, negative, or inconclusive result. In IRD, where the same diagnosis can carry different implications for different families, that conversation is not optional.
The study also points to a health-system issue in Singapore. If patients support testing more strongly when coverage and availability are explicit, then policy design may influence acceptance as much as individual counseling does. Broad access is not only an administrative question; it is part of how patients judge whether testing belongs in routine care.
One limitation is clear from the design itself. This was a cross-sectional survey from a single national setting, so the findings describe attitudes at one point in time rather than behavior after counseling or actual uptake after referral. Even so, the pattern is useful: patients with IRD in Singapore generally support genetic testing, and their support rises when the test feels understandable, covered, and available as part of normal care.